The addition of tesa Labtec GmbH marks a cornerstone in AdhexPharma’s growth path

AdhexPharma and Labtec

September 16th, 2022, Chenôve, France — AdhexPharma S.A.S (“AdhexPharma”) announces that they have signed a binding agreement for the acquisition of 100% of the shares of tesa Labtec GmbH (“tesa Labtec”) located in Langenfeld and Hamburg, Germany.

With this acquisition, AdhexPharma, a leading pharmaceutical company that creates cutting-edge drug delivery systems and oral thin films, joins forces with tesa Labtec GmbH, a well-known CDMO company offering formulation, development, and contract manufacturing services of transdermal and topical patches as well as buccal and sublingual films.

This acquisition complements AdhexPharma's prior acquisition of the AMW assets in strengthening the company's presence in Germany.

AdhexPharma will take over the activities of tesa Labtec, ensuring the continuation of both companies' core businesses, nurturing their recognised know-how, in collaboration with current employees and customers. Both companies will benefit not only from a strong expertise synergy, but also from a robust pipeline of projects in development to accelerate growth.

Bruno Loiseau, Managing Director of AdhexPharma, stated: “We are thrilled to welcome the tesa Labtec team on board. We will benefit from Labtec GmbH’s long-standing expertise in formulating patches and oral films. We will also integrate the management of controlled substances into our portfolio, allowing us to provide an even broader range of services to our clients while also offering additional innovation and development expertise to players developing innovative therapies and new drug delivery systems. This exciting partnership will also provide a great opportunity to leverage tesa Labtec’s transdermal product portfolio with AdhexPharma’s expertise and manufacturing capabilities to enable broader market and patient access for the products.”


Detlev Radloff, Managing Director of tesa Labtec, added: “AdhexPharma being one of the clear leaders in the transdermal industry, we immediately recognised in them the possibility of a transition that seemed logical to us. Their substantial production capacity will be able to handle tesa Labtec’s robust pipeline and meet the ever-growing needs of patients worldwide. With AdhexPharma's goals aligned with our own, we are confident that this combining of forces will be a success and allow us to meet and exceed our customers' expectations by developing innovative drugs beneficial to patients.”

As a result of the acquisition, tesa Labtec's Langenfeld and Hamburg sites will join AdhexPharma's Franco-German network of operations, along with AdhexPharma's existing facilities in Dijon and Paris, France, and Warngau, Germany.

The transaction has received all necessary regulatory approvals and is set to close on September 30, 2022. The transaction's financial details are not disclosed.

AdhexPharma was advised by Milbank LLP (Legal), Novacos Law (Legal), RSM (Financial, Tax) and Klokkers Pharma (Pharmaceutical consulting).


About AdhexPharma

AdhexPharma is a pharmaceutical company specializing in the development and manufacturing of transdermal patches, oral thin films and hard-to-make dosage forms. As such AdhexPharma provides its customers with an industrial, technology expertise and know-how in the formulation, development, and commercial production of such systems. It is cGMP compliant, for both Europe and US and can handle both highly potent APIs and narcotics.

Founded in 2007 for the purpose of acquiring the transdermal patch unit of Solvay in France, AdhexPharma currently manufactures five approved products representing more than 80 million units per year. AdhexPharma is headquartered in Paris and operates industrial activities in facilities located south of Dijon, France and south of Munich, Germany.

AdhexPharma is part of Burgundy Ventures, an independent French industrial holding, along with its sister company Adhex.


About tesa Labtec GmbH

tesa Labtec undertakes the development and manufacture of film-shaped dosage forms (CDMO services) such as transdermal and topical patches as well as oral, buccal or sublingual films. Business activities comprise formulation development, scale-up and manufacture of clinical trial supplies or finished products under full cGMP conditions, for which tesa Labtec relies on its proprietary technologies: Transfilm®, Rapidfilm® and Mucofilm®. tesa Labtec is a wholly owned subsidiary of tesa SE. tesa SE is an independent 100% affiliate of Beiersdorf AG (i.e., NIVEA, Eucerin, la prairie) 


Contact: Mr. Patrick Amberg